The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Long-term responders and survivors on pazopanib for soft tissue sarcomas (STS): Subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.
Bernd Kasper
Honoraria - GlaxoSmithKline
Saskia Litière
No relevant relationships to disclose
Sandrine Marreaud
No relevant relationships to disclose
Stefan Sleijfer
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Jaap Verweij
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Expert Testimony - GlaxoSmithKline
Sebastian Bauer
Honoraria - GlaxoSmithKline; Novartis; Pfizer; PharmaMar
Expert Testimony - GlaxoSmithKline (U)
Jan M. Kerst
No relevant relationships to disclose
Winette T.A. Van Der Graaf
No relevant relationships to disclose